title: Dissociation of augmented physiological, hormonal and cognitive responses to hypoglycaemia with sustained caffeine use.
abstract: In patients with Type I diabetes and healthy volunteers, ingestion of modest amounts of caffeine augments the usual symptomatic and counter-regulatory responses to hypoglycaemia. The aim of the present study was to determine whether these are lost with sustained caffeine use, i.e. does tolerance develop? Eleven healthy caffeine consumers underwent two identical hyperinsulinaemic glucose clamp procedures. For 7 days prior to each clamp, subjects consumed a caffeine-free diet supplemented with 200 mg of caffeine capsules twice daily (caffeine-replete) or placebo (caffeine-withdrawn). During each clamp, blood glucose was held for 80 min at 4.5 mmol/l and then 2.5 mmol/l. At 85 min, subjects were given a 200 mg caffeine capsule. Measurements were taken of symptoms, plasma catecholamine, middle cerebral artery blood velocity (V(MCA)) and cognition. Following the acute caffeine challenge and during hypoglycaemia, V(MCA) fell only in the caffeine-withdrawn condition [-5.1 (-7.3, -3.0) cm/s compared with -1.9 (-4.0, +0.2) cm/s in caffeine-replete condition; P <0.04; values are differences (95% confidence intervals)]. Plasma catecholamine levels and global cognitive performance were unaffected by caffeine status, whereas tests of executive intellectual function were better preserved during hypoglycaemia in the caffeine-replete condition ( P <0.05). The influence of caffeine on hypoglycaemic symptomatic awareness depended upon the duration of the hypoglycaemic stimulus. At onset, symptoms were more intense in caffeine-withdrawn state ( P <0.01); however, with increasing duration of hypoglycaemia, symptom intensity was greater in caffeine-replete condition ( P <0.05). Thus previous caffeine consumption influences the physiological and symptomatic responses to acute hypoglycaemia, but complete tolerance does not develop with sustained use.
authors.affiliation: Bournemouth Diabetes and Endocrine Centre, Royal Bournemouth Hospital, Castle Lane East, Bournemouth BH7 7DW, U.K. joanne.watson@tst.nhs.uk
authors.forename: J M
authors.initials: JM
authors.lastname: Watson
authors.forename: R S
authors.initials: RS
authors.lastname: Sherwin
authors.forename: I J
authors.initials: IJ
authors.lastname: Deary
authors.forename: L
authors.initials: L
authors.lastname: Scott
authors.forename: D
authors.initials: D
authors.lastname: Kerr
mesh_terms: D000328:Adult; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002110:Caffeine / Q000097:blood / Q000494:pharmacology*; D002395:Catecholamines / Q000097:blood; D000697:Central Nervous System Stimulants / Q000097:blood / Q000494:pharmacology*; D002536:Cerebral Arteries; D003071:Cognition / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism* / Q000523:psychology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D015309:Glucose Clamp Technique; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007003:Hypoglycemia / Q000378:metabolism / Q000523:psychology; D008297:Male; D011594:Psychometrics; D014796:Visual Perception / Q000187:drug effects
chemical_list: D002395:Catecholamines; D000697:Central Nervous System Stimulants; D002110:Caffeine